AZ’ Farxiga shows CV benefit in diabetes patients
New analysis of trial data highlight cardiovascular benefits of AstraZeneca’s diabetes drug Farxiga.
Read More
Tag: DECLARE-TIMI 58
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
